— Know what they know.
Not Investment Advice

ORGS OTC

Orgenesis Inc.
1W: +16.0% 1M: +65.7% 3M: +45.0% YTD: +286.7% 1Y: -26.6% 3Y: -90.7% 5Y: -98.8%
$0.58
+0.03 (+5.45%)
 
Weekly Expected Move ±739.3%
$-8 $-4 $1 $5 $9
OTC · Healthcare · Biotechnology · Tech Score Buy · Power 67 · $5.7M mcap · 7M float · 0.0071% daily turnover · Short 76% of daily vol

Cash Flow Trends

Operating Cash Flow
-$15M +40.5% ▲
Capital Expenditures
$2M +83.1% ▲
5Y CAGR: -17.7%
Free Cash Flow
-$17M +54.7% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$5M -1338.0% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2019FY2020FY2021FY2022FY2023
— Operating Activities —
Net Income-$26M$579K-$18M-$12M-$65M
Depreciation & Amort.$4M$1M$2M$2M$2M
Stock-Based Comp.$6M$20M$2M$982K$463K
Change in Working Capital$3M-$3M-$15M-$20M$37M
Other Non-Cash Items$48K$941K$503K$4M$11M
Operating Cash Flow-$13M-$78M-$27M-$25M-$15M
— Investing Activities —
Capital Expenditures-$12M-$2M-$8M-$12M-$2M
Acquisitions (Net)$13M$105M-$242K$862K$0
Investment Purchases-$2M-$551K-$28K-$14K-$33K
Investment Sales-$12M$18K$0$1M$0
Other Investing-$2M$3M-$4M-$4M-$2M
Investing Cash Flow-$14M$106M-$12M-$14M-$4M
— Financing Activities —
Net Debt Issuance$11M-$3M-$1M$17M$3M
Stock Repurchased$0-$250K-$1M$0$0
Dividends Paid$0$0$0$0$0
Other Financing$13M$0$0$21M$5M
Financing Cash Flow$24M$6M-$106K$40M$14M
Net Change in Cash-$3M$34M-$40M$395K-$5M
Cash End of Period$12M$46M$6M$6M$1M
Free Cash Flow-$25M-$80M-$35M-$37M-$17M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms